PriceTargets.com logo

Syndax Pharmaceuticals - SNDX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $35.90
  • Forecasted Upside: 89.15%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$18.98 As of 10/30/2024 03:58 PM ET
▼ -0.1 (-0.52%)

This chart shows the closing price for SNDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Syndax Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNDX

Analyst Price Target is $35.90
▲ +89.15% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $35.90, with a high forecast of $45.00 and a low forecast of $23.00. The average price target represents a 89.15% upside from the last price of $18.98.

This chart shows the closing price for SNDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Syndax Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/24/2024UBS GroupInitiated CoverageBuy$37.00
10/14/2024Stifel NicolausBoost TargetBuy ➝ Buy$40.00 ➝ $41.00
8/16/2024CitigroupBoost TargetBuy ➝ Buy$30.00 ➝ $34.00
8/15/2024Bank of AmericaBoost TargetBuy ➝ Buy$30.00 ➝ $31.00
8/15/2024HC WainwrightBoost TargetBuy ➝ Buy$41.00 ➝ $45.00
8/15/2024BarclaysBoost TargetOverweight ➝ Overweight$32.00 ➝ $33.00
8/6/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$34.00 ➝ $33.00
7/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
6/28/2024Jefferies Financial GroupInitiated CoverageBuy$37.00
6/26/2024Stifel NicolausBoost TargetBuy ➝ Buy$40.00 ➝ $42.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
6/14/2024ScotiabankDowngradeStrong-Buy ➝ Hold
6/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00 ➝ $41.00
5/21/2024JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$34.00 ➝ $34.00
5/9/2024CitigroupLower TargetBuy ➝ Buy$32.00 ➝ $30.00
5/9/2024Stifel NicolausBoost TargetBuy ➝ Buy$39.00 ➝ $40.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00
4/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00
3/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$31.00 ➝ $34.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00
1/31/2024ScotiabankDowngradeSector Outperform ➝ Sector Perform$36.00 ➝ $23.00
1/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$41.00
12/22/2023HC WainwrightLower TargetBuy ➝ Buy$42.00 ➝ $41.00
12/22/2023MizuhoInitiated CoverageBuy$45.00
10/26/2023Stifel NicolausLower TargetBuy ➝ Buy$38.00 ➝ $36.00
10/25/2023Bank of AmericaInitiated CoverageBuy$29.00
10/17/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$36.00 ➝ $38.00
10/11/2023The Goldman Sachs GroupInitiated CoverageBuy$30.00
10/3/2023ScotiabankLower Target$39.00 ➝ $36.00
10/3/2023GuggenheimBoost Target$42.00 ➝ $43.00
10/3/2023Robert W. BairdLower Target$32.00 ➝ $28.00
10/2/2023HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $42.00
8/16/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$36.00 ➝ $33.00
8/4/2023HC WainwrightReiterated RatingBuy$38.00
7/27/2023ScotiabankInitiated CoverageOutperform
7/26/2023CitigroupBoost Target$31.00 ➝ $34.00
7/26/2023BarclaysBoost TargetOverweight$31.00 ➝ $34.00
7/25/2023B. RileyBoost TargetBuy$34.00 ➝ $36.00
7/24/2023GuggenheimBoost TargetBuy$40.00 ➝ $42.00
7/24/2023HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $38.00
7/10/2023GuggenheimInitiated CoverageBuy$40.00
5/10/2023CitigroupLower Target$32.00 ➝ $31.00
5/9/2023HC WainwrightBoost Target$33.00 ➝ $36.00
3/7/2023JPMorgan Chase & Co.Lower TargetOverweight$41.00 ➝ $36.00
3/2/2023CitigroupBoost TargetBuy$29.00 ➝ $32.00
3/1/2023HC WainwrightReiterated RatingBuy$33.00
3/1/2023The Goldman Sachs GroupLower TargetBuy$39.00 ➝ $34.00
1/30/2023Stifel NicolausInitiated CoverageBuy$37.00
1/3/2023JPMorgan Chase & Co.Initiated CoverageOverweight$41.00
12/12/2022The Goldman Sachs GroupBoost TargetBuy$35.00 ➝ $39.00
12/12/2022HC WainwrightBoost TargetBuy$31.00 ➝ $33.00
8/15/2022Robert W. BairdBoost Target$32.00
8/9/2022The Goldman Sachs GroupLower TargetBuy$40.00 ➝ $35.00
7/28/2022B. RileyReiterated RatingBuy$31.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$51.00 ➝ $40.00
4/11/2022HC WainwrightInitiated CoverageBuy$31.00
2/15/2022The Goldman Sachs GroupInitiated CoverageBuy$37.00
10/12/2021Morgan StanleyBoost TargetEqual Weight$20.00 ➝ $21.00
5/25/2021CitigroupInitiated CoverageBuy
5/13/2021Robert W. BairdReiterated RatingBuy$30.00
5/12/2021Morgan StanleyLower TargetEqual Weight$25.00 ➝ $20.00
4/21/2021B. RileyReiterated RatingBuy
4/21/2021Robert W. BairdLower TargetOutperform$39.00 ➝ $30.00
2/18/2021B. RileyInitiated CoverageBuy$30.00
12/8/2020Smith Barney CitigroupBoost TargetBuy$23.00 ➝ $31.00
12/7/2020Morgan StanleyBoost TargetEqual Weight$17.00 ➝ $25.00
12/7/2020BTIG ResearchBoost TargetBuy$26.00 ➝ $32.00
12/7/2020BarclaysBoost TargetOverweight$29.00 ➝ $31.00
12/2/2020Stifel NicolausInitiated CoverageBuy$32.00
11/19/2020BarclaysBoost TargetOverweight$23.00 ➝ $29.00
11/4/2020Morgan StanleyBoost TargetEqual Weight$16.00 ➝ $17.00
5/29/2020Morgan StanleyLower TargetEqual Weight$22.00 ➝ $16.00
5/25/2020NomuraReiterated RatingBuy$31.00
5/22/2020HC WainwrightDowngradeBuy ➝ Neutral$25.00 ➝ $15.00
5/22/2020BarclaysLower TargetOverweight$25.00 ➝ $23.00
5/22/2020CitigroupUpgradeNeutral ➝ Buy$26.00 ➝ $23.00
5/21/2020Morgan StanleyBoost TargetEqual Weight$10.00 ➝ $22.00
5/18/2020CitigroupDowngradeBuy ➝ Neutral$26.00
5/11/2020HC WainwrightBoost TargetBuy$19.00 ➝ $25.00
5/8/2020NomuraBoost Target$16.00 ➝ $31.00
4/30/2020NomuraReiterated RatingBuy$16.00
4/28/2020HC WainwrightBoost TargetBuy$18.00 ➝ $19.00
4/28/2020Robert W. BairdBoost TargetOutperform$27.00 ➝ $33.00
4/21/2020HC WainwrightReiterated RatingBuy$18.00
3/26/2020Nomura SecuritiesReiterated RatingBuy$16.00
3/12/2020CitigroupBoost Target$12.00 ➝ $18.00
3/11/2020Morgan StanleyBoost TargetEqual Weight$8.00 ➝ $10.00
3/4/2020HC WainwrightReiterated RatingBuy$18.00
3/4/2020Robert W. BairdBoost TargetOutperform$20.00 ➝ $27.00
3/4/2020BarclaysInitiated CoverageOverweight$15.00
2/3/2020HC WainwrightReiterated RatingBuy$17.00
1/13/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $17.00
12/10/2019HC WainwrightReiterated RatingBuy$15.00
11/8/2019CowenReiterated RatingBuy
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 9 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 12 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 9 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 8 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Syndax Pharmaceuticals logo
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $18.98
Low: $18.78
High: $19.11

50 Day Range

MA: $19.20
Low: $17.93
High: $20.93

52 Week Range

Now: $18.98
Low: $12.95
High: $25.34

Volume

175,044 shs

Average Volume

1,049,468 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Syndax Pharmaceuticals?

The following Wall Street research analysts have issued reports on Syndax Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Scotiabank, Stifel Nicolaus, StockNews.com, and UBS Group AG.
View the latest analyst ratings for SNDX.

What is the current price target for Syndax Pharmaceuticals?

10 Wall Street analysts have set twelve-month price targets for Syndax Pharmaceuticals in the last year. Their average twelve-month price target is $35.90, suggesting a possible upside of 89.1%. Mizuho has the highest price target set, predicting SNDX will reach $45.00 in the next twelve months. Scotiabank has the lowest price target set, forecasting a price of $23.00 for Syndax Pharmaceuticals in the next year.
View the latest price targets for SNDX.

What is the current consensus analyst rating for Syndax Pharmaceuticals?

Syndax Pharmaceuticals currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SNDX.

What other companies compete with Syndax Pharmaceuticals?

Other companies that are similar to Syndax Pharmaceuticals include Enanta Pharmaceuticals, Elanco Animal Health, Cytokinetics, Nuvalent and Blueprint Medicines. Learn More about companies similar to Syndax Pharmaceuticals.

How do I contact Syndax Pharmaceuticals' investor relations team?

Syndax Pharmaceuticals' physical mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company's listed phone number is (781) 419-1400 and its investor relations email address is [email protected]. The official website for Syndax Pharmaceuticals is www.syndax.com. Learn More about contacing Syndax Pharmaceuticals investor relations.